Newswise — ANN ARBOR, Mich. -- At the American College of Cardiology Scientific Sessions April 2-4 in Chicago, University of Michigan Frankel Cardiovascular Center physicians will be available for media interviews on the cutting-edge advances and practice-changing updates being highlighted.
University of Michigan researchers are ready to discuss the research they’re presenting on minimally invasive aortic valve repair, known as TAVR, and put into perspective the impact of late-breaking trials on atrial fibrillation and electrophysiology, hypertension, preventative cardiology, heart attack treatment and heart failure.
“One of the great aha moments in my life was seeing the difference between a post-procedure transcatheter aortic valve patient versus a surgical valve patient,” says G. Michael Deeb, M.D., professor of cardiac surgery at the University of Michigan Frankel Cardiovascular Center. “After the procedure they’re ready to go. They want to go home. They want to get back into life. It’s that dramatic.”
A nationally known cardiac surgeon, Deeb will present 3-year results of the CoreValve U.S. Pivotal High Risk trial during ACC on Sunday, April 3.
The surgeons and interventional cardiologists at the U-M Frankel Cardiovascular Center have performed more than 640 TAVR procedures, making the U-M one of the busiest programs in the country. The U-M participated in the clinical trials leading to the TAVR devices on the market today.
To connect with physicians for phone or on-camera interviews or obtain photography of common heart procedures such as TAVR or ablation for atrial fibrillation, please contact media relations lead for the U-M Cardiovascular Center who will be in Chicago at the Sessions.
Shantell M. KirkendollEmail: [email protected]Mobile: (810) 210-7760 ###
RSS